
Takeaways
Crucial Regulation: By regulating free haem levels, albumin’s haem site limits cellular damage.
Allosteric Interactions: The haem site is linked to other binding sites which means changes at adjacent sites can directly impact haem transport.
Nutrition Consequences: Changes to albumin's haem site can impact the carrying capacity of other nutrients, with consequent nutritional and clinical implications.
Albumin’s haem site is important in regulating free haem levels within our blood.
Haem Overview
Haem sources
Free haem sources include newly-produced haem for integration into haemoproteins, and recently released haem from haemoproteins.
Factors that increase haem levels include increased haem production, increased haemoprotein breakdown, and impaired haem uptake.
Haem’s functions
Haem’s functions include -
- oxygen transport in the blood utilising haemoglobin;
- oxygen storage in the tissues utilising myoglobin;
- producing cytochrome P450 enzymes responsible for the metabolism of external substances;
- immune function processes including immune-receptor sensing;
- red blood cell activation and regulation;
- inducing cell signalling and sensing pathways;
- modifying oxidative stress by sequestering active iron before it causes reactive oxygen species to form.
Excessive haem
Excessive free haem is extremely toxic for cells, mostly resulting in cell death, as it -
(i) disrupts the lipids in the cell membranes;
(ii) has pro-inflammatory properties;
(iii) impairs the functions of blood vessels;
(iv) causes oxidative damage to cells.
Consequently, haem levels are very tightly regulated to optimize cellular function and minimize negative physiological impacts.
Regulatory systems
Albumin’s contribution to haem regulation is to bind and remove excess amounts from the blood.
Excessive haem levels are also managed by their binding to high-density lipoproteins (HDL), low-density lipoproteins (LDL), hemopexin, and albumin. The plasma initially binds 80+% of the haem to HDL and LDL, and the remainder to hemopexin and albumin. Albumin then transfers the haem from HDL and LDL to hemopexin for delivery to the liver for degradation or recycling.

Haem Site
Haem site is also known as the haem binding pocket, haem pocket, FA1 (fatty acid binding site 1) and is located in subdomain IB.
Some fatty acids, bilirubin, biliverdin, haem, hemin, methyl orange and several pharmaceuticals can be carried on the haem site.
FA1, FA2, FA3-4, and FA7 are functionally and allosterically linked. Consequently, binding on one site is likely to alter binding capabilities on the other sites. Ultimately allosteric impact may not be a straightforward association. Some evidence indicates drug-induced allosteric inhibition of haem binding to albumin only occurs when albumin levels are low.
Haem binding to albumin is altered by, or can inhibit, compounds binding to the FA2, FA3-4 and FA7 sites. For example, substances binding to albumin’s site on –
- FA1 - directly impair haem binding,
- FA7 - allosterically decrease haem binding.
Clinical Concerns
The research on allosteric impacts on albumin’s carrying capacity of nutritional factors is remarkably limited. This inadequacy of evidence means optimization of the pharmaceutical therapeutic benefits cannot be realized.
Clinical Questions
When you a review a person’s prescribed medicines that directly or indirectly affect the haem site, would you question -
- whether they are also altering albumin’s capacity to carry the Mineral binding site-A (MBS-A)-bound nutrients (calcium, cobalt, copper, magnesium, manganese, zinc) thus altering their availability?
Conclusions
Albumin’s haem site is important in a range of physiological functions, and its alteration can have significant nutritional consequences.
Bibliography
Lemli B., Lomozová, Z., Huber, T., Lukács, A. & Poór, M. 2022. Effects of Heme Site (FA1) Ligands Bilirubin, Biliverdin, Hemin, and Methyl Orange on the Albumin Binding of Site I Marker Warfarin: Complex Allosteric Interactions. International Journal of Molecular Science 23(22):14007. https://doi.org/10.3390/ijms232214007. PMID: 36430492; PMCID: PMC9694159.
De Simone, G., Varricchio, R., Ruberto ,TF., di Masi, A. & Ascenzi, P. 2023. Heme Scavenging and Delivery: The Role of Human Serum Albumin. Biomolecules 13(3):575. https://doi.org/10.3390/biom13030575. PMID: 36979511; PMCID: PMC10046553.
Ascenzi, P., di Masi, A., Fanali, G. & Fasano, M. 2015. Heme-based catalytic properties of human serum albumin. Cell Death Discovy 1:15025. doi: 10.1038/cddiscovery.2015.25. PMID: 27551458; PMCID: PMC4991842
Awasthi, S. & Saraswathi, NT, 2016. Non-enzymatic glycation mediated structure–function changes in proteins: case of serum albumin. Royal Society of Chemistry Advances 6(93):90739-90753. https://doi.org/10.1039/c6ra08283a
Belinskaia, DA., Voronina, PA., Shmurak, VI., Jenkins, RO. & Goncharov, NV. 2021. Serum Albumin in Health and Disease: Esterase, Antioxidant, Transporting and Signaling Properties. International Journal of Molecular Science 22:10318. https://doi.org/10.3390/ijms221910318
De Simone, G., di Masi, A. & Ascenzi, P. 2021. Serum Albumin: A Multifaced Enzyme. International Journal of Molecular Science 22:10086. https://doi.org/10.3390/ijms221810086
Ashraf, S., Qaiser, H., Tariq, S., Khalid, A., Makeen, GA., Alhazmi, HA. & Ul-Haq, Z. 2023. Unraveling the versatility of human serum albumin – A comprehensive review of its biological significance and therapeutic potential. Current Research in Structural Biology 6:100114. Doi 10.1016/j.crstbi.2023.100114
Pinsky, M., Roy, U., Moshe, S., Weissman, Z. & Kornitzer, D. 2020. Human serum albumin facilitates heme-iron utilization by fungi. mBio 11:e00607-20. https://doi.org/10.1128/mBio.00607-20.
Tsiftsoglou, SA. & Tsiftsoglou, AS. 2025. Multiple classes of human intracellular Heme-binding proteins with pathology-associated polymorphisms of heme coordinating residues. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1871(5): 167799. https://doi.org/10.1016/j.bbadis.2025.167799
Shetty, T. & Corson, TW. 2020. Mitochondrial Heme Synthesis Enzymes as Therapeutic Targets in Vascular Diseases. Frontiers in Pharmacology 11:1015. https://doi.org/10.3389/fphar.2020.01015
Ali, SF., White, AE., Medlock, A. & Khalimonchuk, O. 2025. Mechanisms of heme transport in the mitochondria. Biochemical Society Transactions 53(3):603-614. https://doi.org/10.1042/BST20253013. PMID: 40440032; PMCID: PMC12224909.
Cite: Coleman, Y. 2025. Albumin's haem site. MedNut Mail https://medicationsandnutrition.com/albumins-haem-site/ Accessed (date)
Albumin's haem site


